MK 571
Alternative Names: L 660711Latest Information Update: 25 Oct 2018
At a glance
- Originator Merck Frosst
- Developer Banyu; Merck Frosst
- Class Antiasthmatics; Antiulcers
- Mechanism of Action Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Atherosclerosis
Most Recent Events
- 29 Mar 2010 Discontinued - Phase-II for Asthma in Canada (IV)
- 29 Mar 2010 Discontinued - Phase-II for Asthma in Canada (PO)
- 12 Feb 1997 Suspended-II for Asthma in Canada (IV)